As shown in Fig. 4, tumor growth delay was best for mice receiving CS1 CAR T cells 21 days post 225Ac-CD38 TAT (28 days post tumor engraftment) with an overall survival of 91 days compared to 42 days for untreated controls (Fig. 4A–C, Fig. S4, Table S1). The gene discussed is CD38; the disease is neoplasm.